Quantum dots induced monocyte chemotactic protein-1 expression via MyD88-dependent Toll-like receptor signaling pathways in macrophages

Toxicology

Volumn 308, Issue , 2013, Pages 1-9

  Ho, Chia Chi ^a   Luo, Yueh Hsia ^b   Chuang, Tsung Hsien ^b   Yang, Chung Shi ^b   Ling, Yong Chien ^a   Lin, Pinpin ^b  

^a NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

Inflammation; MCP 1; MyD88; NF B; QD705; TLRs

Indexed keywords

3 (4 TERT BUTYLPHENYLSULFONYL) 2 PROPENENITRILE; AGENTS AFFECTING METABOLISM; CHLOROQUINE; CLI 095; CYTOCHALASIN B; DYNASORE; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MACROGOL; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOID DIFFERENTIATION FACTOR 88; POLYMYXIN B; QUANTUM DOT; QUANTUM DOT 705; SMALL INTERFERING RNA; SYNAPTOTAGMIN I; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL SURFACE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENDOCYTOSIS; GENE SILENCING; INFLAMMATION; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION;

ANIMALS; CELL LINE; CHEMOKINE CCL2; CHROMOGENIC COMPOUNDS; GENE EXPRESSION REGULATION; MACROPHAGES; MICE; MYELOID DIFFERENTIATION FACTOR 88; PARTICLE SIZE; QUANTUM DOTS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 84876708985     PISSN: 0300483X     EISSN: 18793185     Source Type: Journal    
DOI: 10.1016/j.tox.2013.03.003     Document Type: Article

References (56)

1. Abdollahi-Roodsaz S., van de Loo F.A., Koenders M.I., Helsen M.M., Walgreen B., van den Bersselaar L.A., Arntz O.J., Takahashi N., Joosten L.A., van den Berg W.B. Destructive role of myeloid differentiation factor 88 and protective role of TRIF in interleukin-17-dependent arthritis in mice. Arthritis Rheum. 2012, 64:1838-1847.
2. An H., Xu H., Yu Y., Zhang M., Qi R., Yan X., Liu S., Wang W., Guo Z., Qin Z., Cao X. Up-regulation of TLR9 gene expression by LPS in mouse macrophages via activation of NF-κB, ERK and p38 MAPK signal pathways. Immunol. Lett. 2002, 81:165-169.
3. Ballou B., Lagerholm B.C., Ernst L.A., Bruchez M.P., Waggoner A.S. Noninvasive imaging of quantum dots in mice. Bioconjug. Chem. 2004, 15:79-86.
4. Blasius A.L., Beutler B. Intracellular toll-like receptors. Immunity 2010, 32:305-315.
5. Castillo P.M., Herrera J.L., Fernandez-Montesinos R., Caro C., Zaderenko A.P., Mejias J.A., Pozo D. Tiopronin monolayer-protected silver nanoparticles modulate IL-6 secretion mediated by Toll-like receptor ligands. Nanomedicine (Lond.) 2008, 3:627-635.
6. Cedervall T., Lynch I., Lindman S., Berggard T., Thulin E., Nilsson H., Dawson K.A., Linse S. Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:2050-2055.
7. Clift M.J., Boyles M.S., Brown D.M., Stone V. An investigation into the potential for different surface-coated quantum dots to cause oxidative stress and affect macrophage cell signalling in vitro. Nanotoxicology 2010, 4:139-149.
8. Cook D.N., Pisetsky D.S., Schwartz D.A. Toll-like receptors in the pathogenesis of human disease. Nat. Immunol. 2004, 5:975-979.
9. Cooperstock M.S. Inactivation of endotoxin by polymyxin B. Antimicrob. Agents Chemother. 1974, 6:422-425.
10. 2 nanoparticles. J. Biomed. Mater. Res. A 2011, 96:221-229.
11. Di Gioacchino M., Petrarca C., Lazzarin F., Di Giampaolo L., Sabbioni E., Boscolo P., Mariani-Costantini R., Bernardini G. Immunotoxicity of nanoparticles. Int. J. Immunopathol. Pharmacol. 2011, 24:65S-71S.
12. Dobrovolskaia M.A., Germolec D.R., Weaver J.L. Evaluation of nanoparticle immunotoxicity. Nat. Nanotechnol. 2009, 4:411-414.
13. Fischer H.C., Hauck T.S., Gomez-Aristizabal A., Chan W.C. Exploring primary liver macrophages for studying quantum dot interactions with biological systems. Adv. Mater. 2010, 22:2520-2524.
14. Gao X., Cui Y., Levenson R.M., Chung L.W., Nie S. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat. Biotechnol. 2004, 22:969-976.
15. Hanaki K., Momo A., Oku T., Komoto A., Maenosono S., Yamaguchi Y., Yamamoto K. Semiconductor quantum dot/albumin complex is a long-life and highly photostable endosome marker. Biochem. Biophys. Res. Commun. 2003, 302:496-501.
16. Hasegawa M., Sato S., Takehara K. Augmented production of chemokines (monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1α (MIP-1α) and MIP-1β) in patients with systemic sclerosis MCP-1 and MIP-1α may be involved in the development of pulmonary fibrosis. Clin. Exp. Immunol. 1999, 117:159-165.
17. He X., Young S.H., Schwegler-Berry D., Chisholm W.P., Fernback J.E., Ma Q. Multiwalled carbon nanotubes induce a fibrogenic response by stimulating reactive oxygen species production, activating NF-κB signaling, promoting fibroblast-to-myofibroblast transformation. Chem. Res. Toxicol. 2011, 24:2237-2248.
18. Hilderbrand S.A., Weissleder R. Near-infrared fluorescence application to in vivo molecular imaging. Curr. Opin. Chem. Biol. 2010, 14:71-79.
19. Ho C.C., Chang H., Tsai H.T., Tsai M.H., Yang C.S., Ling Y.C., Lin P. Quantum dot 705, a cadmium-based nanoparticle, induces persistent inflammation and granuloma formation in the mouse lung. Nanotoxicology 2013, 7:105-115.
20. Iwasaki A., Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 2004, 5:987-995.
21. Kagan V.E., Bayir H., Shvedova A.A. Nanomedicine and nanotoxicology two sides of the same coin. Nanomedicine 2005, 1:313-316.
22. Kamata H., Tasaka S., Inoue K., Miyamoto K., Nakano Y., Shinoda H., Kimizuka Y., Fujiwara H., Ishii M., Hasegawa N., Takamiya R., Fujishima S., Takano H., Ishizaka A. Carbon black nanoparticles enhance bleomycin-induced lung inflammatory and fibrotic changes in mice. Exp. Biol. Med. (Maywood) 2011, 236:315-324.
23. Kawamoto T., Ii M., Kitazaki T., Iizawa Y., Kimura H. TAK-242 selectively suppresses Toll-like receptor 4-signaling mediated by the intracellular domain. Eur. J. Pharmacol. 2008, 584:40-48.
24. Kohler N., Sun C., Fichtenholtz A., Gunn J., Fang C., Zhang M. Methotrexate-immobilized poly(ethylene glycol) magnetic nanoparticles for MR imaging and drug delivery. Small 2006, 2:785-792.
25. Kumar H., Kawai T., Akira S. Toll-like receptors and innate immunity. Biochem. Biophys. Res. Commun. 2009, 388:621-625.
26. Lam C.W., James J.T., McCluskey R., Hunter R.L. Pulmonary toxicity of single-wall carbon nanotubes in mice 7 and 90 days after intratracheal instillation. Toxicol. Sci. 2004, 77:126-134.
27. Lamkanfi M., Dixit V.M. Modulation of inflammasome pathways by bacterial and viral pathogens. J. Immunol. 2011, 187:597-602.
28. Lin C.H., Yang M.H., Chang L.W., Yang C.S., Chang H., Chang W.H., Tsai M.H., Wang C.J., Lin P. Cd/Se/Te-based quantum dot 705 modulated redox homeostasis with hepatotoxicity in mice. Nanotoxicology 2011, 5:650-663.
29. Lucarelli M., Gatti A.M., Savarino G., Quattroni P., Martinelli L., Monari E., Boraschi D. Innate defence functions of macrophages can be biased by nano-sized ceramic and metallic particles. Eur. Cytokine Netw. 2004, 15:339-346.
30. Lundqvist M., Stigler J., Elia G., Lynch I., Cedervall T., Dawson K.A. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:14265-14270.
31. Lupfer C.R., Kanneganti T.D. The role of inflammasome modulation in virulence. Virulence 2012, 3:262-270.
32. Makela S.M., Strengell M., Pietila T.E., Osterlund P., Julkunen I. Multiple signaling pathways contribute to synergistic TLR ligand-dependent cytokine gene expression in human monocyte-derived macrophages and dendritic cells. J. Leukoc. Biol. 2009, 85:664-672.
33. Maslanik T., Tannura K., Mahaffey L., Loughridge A.B., Benninson L., Ursell L., Greenwood B.N., Knight R., Fleshner M. Commensal bacteria and MAMPs are necessary for stress-induced increases in IL-1beta and IL-18 but not IL-6, IL-10 or MCP-1. PLoS One 2012, 7:e50636.
34. Michelsen K.S., Wong M.H., Shah P.K., Zhang W., Yano J., Doherty T.M., Akira S., Rajavashisth T.B., Arditi M. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:10679-10684.
35. Mulder W.J., Strijkers G.J., Nicolay K., Griffioen A.W. Quantum dots for multimodal molecular imaging of angiogenesis. Angiogenesis 2010, 13:131-134.
36. Muller J., Huaux F., Moreau N., Misson P., Heilier J.F., Delos M., Arras M., Fonseca A., Nagy J.B., Lison D. Respiratory toxicity of multi-wall carbon nanotubes. Toxicol. Appl. Pharmacol. 2005, 207:221-231.
37. Murray A.R., Kisin E., Leonard S.S., Young S.H., Kommineni C., Kagan V.E., Castranova V., Shvedova A.A. Oxidative stress and inflammatory response in dermal toxicity of single-walled carbon nanotubes. Toxicology 2009, 257:161-171.
38. Obonyo O., Fisher E., Edwards M., Douroumis D. Quantum dots synthesis and biological applications as imaging and drug delivery systems. Crit. Rev. Biotechnol. 2010, 30:283-301.
39. Owens D.E., Peppas N.A. Opsonization, biodistribution, pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. 2006, 307:93-102.
40. Pahl H.L. Activators and target genes of Rel/NF-κB transcription factors. Oncogene 1999, 18:6853-6866.
41. Patel J.K., Clifford R.L., Deacon K., Knox A.J. Ciclesonide inhibits TNFα- and IL-1β-induced monocyte chemotactic protein-1 (MCP-1/CCL2) secretion from human airway smooth muscle cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 2012, 302:L785-L792.
42. Premkumar V., Dey M., Dorn R., Raskin I. MyD88-dependent and independent pathways of Toll-Like Receptors are engaged in biological activity of Triptolide in ligand-stimulated macrophages. BMC Chem. Biol. 2010, 10:3.
43. Romoser A.A., Chen P.L., Berg J.M., Seabury C., Ivanov I., Criscitiello M.F., Sayes C.M. Quantum dots trigger immunomodulation of the NFκB pathway in human skin cells. Mol. Immunol. 2011, 48:1349-1359.
44. Rutz M., Metzger J., Gellert T., Luppa P., Lipford G.B., Wagner H., Bauer S. Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence- and pH-dependent manner. Eur. J. Immunol. 2004, 34:2541-2550.
45. Ryman-Rasmussen J.P., Riviere J.E., Monteiro-Riviere N.A. Penetration of intact skin by quantum dots with diverse physicochemical properties. Toxicol. Sci. 2006, 91:159-165.
46. Takeda K., Akira S. Regulation of innate immune responses by Toll-like receptors. Jpn. J. Infect. Dis. 2001, 54:209-219.
47. Takeda K., Akira S. TLR signaling pathways. Semin. Immunol. 2004, 16:3-9.
48. Tetley T.D. Health effects of nanomaterials. Biochem. Soc. Trans. 2007, 35:527-531.
49. Tsai C.Y., Lu S.L., Hu C.W., Yeh C.S., Lee G.B., Lei H.Y. Size-dependent attenuation of TLR9 signaling by gold nanoparticles in macrophages. J. Immunol. 2012, 188:68-76.
50. Wang C., Deng L., Hong M., Akkaraju G.R., Inoue J., Chen Z.J. TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature 2001, 412:346-351.
51. Xiao Y., Forry S.P., Gao X., Holbrook R.D., Telford W.G., Tona A. Dynamics and mechanisms of quantum dot nanoparticle cellular uptake. J. Nanobiotechnol. 2010, 8:13.
52. Xu Y., Rojkind M., Czaja M.J. Regulation of monocyte chemoattractant protein 1 by cytokines and oxygen free radicals in rat hepatic fat-storing cells. Gastroenterology 1996, 110:1870-1877.
53. Xu H., Yan J., Zhu Z., Hussain L.R., Huang Y., Ding C., Bozulic L.D., Wen Y., Ildstad S.T. A critical role for the TLR4/TRIF pathway in allogeneic hematopoietic cell rejection by innate immune cells. Cell Transplant. 2012, [Epub ahead of print].
54. Yamamoto M., Akira S. TIR domain-containing adaptors regulate TLR-mediated signaling pathways. Nihon Rinsho 2004, 62:2197-2203.
55. Yazdi A.S., Guarda G., Riteau N., Drexler S.K., Tardivel A., Couillin I., Tschopp J. Nanoparticles activate the NLR pyrin domain containing 3 (NLRP3) inflammasome and cause pulmonary inflammation through release of IL-1α and IL-1β. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:19449-19454.
56. Zhang H., Yee D., Wang C. Quantum dots for cancer diagnosis and therapy biological and clinical perspectives. Nanomedicine (Lond.) 2008, 3:83-91.